Associated tags: Algorithm, Health, DCTS, Single-frequency network, Pharmaceutical industry, Patient, DCT, Clinical trial, Therapy, Research, Cloud computing, Medical imaging
Retrieved on:
Tuesday, October 31, 2023
Digital,
Research,
Insurance,
Therapy,
Government,
Orchestra,
Mortality,
Conditional sentence,
DTA,
Geography,
Environment,
DCTS,
Clinical trial,
Walking,
Single-frequency network,
Language,
Patient,
Outcome,
Pharmaceutical industry,
Nursing,
Stroke NEW YORK, Oct. 31, 2023 /PRNewswire/ -- Curavit Clinical Research, a virtual contract research organization (VCRO) that specializes in decentralized clinical trials (DCTs) for digital therapeutics (DTx), launches new Health Economics and Outcomes Research (HEOR) Practice. Curavit will incorporate HEOR services in clinical trials to capture evidence of the health economics value of novel pharmaceutical products, especially digital therapeutics which are striving to accelerate market momentum. Curavit will assess the value and effect of DTx interventions on both individual patients and population health levels of care.
Key Points:
- NEW YORK, Oct. 31, 2023 /PRNewswire/ -- Curavit Clinical Research , a virtual contract research organization (VCRO) that specializes in decentralized clinical trials (DCTs) for digital therapeutics (DTx), launches new Health Economics and Outcomes Research (HEOR) Practice.
- Curavit will incorporate HEOR services in clinical trials to capture evidence of the health economics value of novel pharmaceutical products, especially digital therapeutics which are striving to accelerate market momentum.
- Curavit will assess the value and effect of DTx interventions on both individual patients and population health levels of care.
- Curavit and the Digital Therapeutics Alliance will be co-hosting educational events on November 3 in Boston, and December 7 in San Francisco.
Retrieved on:
Wednesday, September 20, 2023
Single-frequency network,
Music,
Partnership,
Institutional review board,
Success,
Clinical trial,
Research,
Brain,
DCT,
DCTS,
Walking,
RAS,
Patient,
IRB,
Orchestra,
Outcome,
Health,
Pharmaceutical industry,
Stroke NEW YORK, Sept. 20, 2023 /PRNewswire/ -- Curavit Clinical Research, a virtual contract research organization (VCRO) that specializes in decentralized clinical trials (DCTs) for digital therapeutics (DTx), announced that it was selected as the VCRO for a study of MR-001, MedRhythms' neurorehabilitation system designed to improve walking and ambulation in adults with chronic stroke walking impairments. The goal of the study is to further characterize the long-term economic and clinical benefits of MR-001 beyond what has been established in a multi-center, randomized clinical trial. This will also include evaluating patient engagement and therapeutic response durability.
Key Points:
- The goal of the study is to further characterize the long-term economic and clinical benefits of MR-001 beyond what has been established in a multi-center, randomized clinical trial.
- Curavit is responsible for managing all aspects of MedRhythms' hybrid decentralized clinical trial (DCT) – from protocol finalization and Institutional Review Board (IRB) approvals to patient recruitment, testing at physical sites, remote site and patient monitoring and healthcare economics and outcomes analysis.
- Health economics research quantifies the long-term financial impact for patients, providers, and payers," said Owen McCarthy, President and co-founder of MedRhythms.
- MR-001 is based on Rhythmic Auditory Stimulation (RAS), a clinical intervention utilizing the mechanism of auditory-motor entrainment ("entrainment").
Single-frequency network,
Advertising,
Therapy,
Marketing,
Clinical trial,
DCTS,
Equity,
Language,
African Americans,
Science,
Patient,
Inclusive,
Japan Contents Review Center,
Brochureware,
Knowledge,
IDEA,
IDE,
FDA,
Health literacy,
IND,
Pharmaceutical industry,
Nursing,
Diversity NEW YORK, June 21, 2023 /PRNewswire/ -- Curavit Clinical Research, a virtual contract research organization (VCRO) that specializes in decentralized clinical trials (DCTs) for digital therapeutics (DTx), announces its Inclusivity, Diversity, and Equity in Action (IDEA) toolkit. IDEA is a comprehensive clinical trial planning and support service designed to help clinical trial sponsors navigate the myriad challenges in developing and executing diversity action plans, now required by law for most clinical trials in the United States.
Key Points:
- IDEA is a comprehensive clinical trial planning and support service designed to help clinical trial sponsors navigate the myriad challenges in developing and executing diversity action plans, now required by law for most clinical trials in the United States.
- In April 2022, the FDA released draft guidance on improving enrollment for participants from underrepresented racial and ethnic populations in clinical trials.
- DEI Implementation Strategy – a streamlined trial execution strategy in alignment with the trial protocol and FDA diversity guidelines.
- "With its unique combination of insights, protocol development support, and planning guides, Curavit's IDEA toolkit is helping companies turn lofty aspiration into action."
DCT,
Tears,
Blood,
Lilly,
Research,
Clinical trial,
Single-frequency network,
Eli Lilly and Company,
Society,
Biopharma LLC,
Perspiration,
Knowledge,
Eli Lilly,
DCTS,
Pharmaceutical industry,
Medidata Solutions NEW YORK, March 7, 2023 /PRNewswire/ -- Curavit Clinical Research, a virtual contract research organization (VCRO) that specializes in decentralized clinical trials (DCTs) for digital therapeutics (DTx), announced the appointment of Jackie Kent to the Curavit Board of Directors. Ms. Kent is the first external fiduciary, independent life sciences industry veteran member on the Curavit Board.
Key Points:
- NEW YORK, March 7, 2023 /PRNewswire/ -- Curavit Clinical Research , a virtual contract research organization (VCRO) that specializes in decentralized clinical trials (DCTs) for digital therapeutics (DTx), announced the appointment of Jackie Kent to the Curavit Board of Directors.
- Ms. Kent is the first external fiduciary, independent life sciences industry veteran member on the Curavit Board.
- With more than 30 years of experience in various technology and clinical research roles across the life sciences industry, Kent brings real-world knowledge to Curavit.
- While at Medidata, Kent also served as vice Chairperson (2021) and chairperson (2022) of the Association of Clinical Research Organizations (ACRO).
Retrieved on:
Monday, November 14, 2022
Veteran,
Growth,
OVP,
CRO,
Technology,
Veeva Systems,
Curio,
Lark Health,
Therapy,
News,
NEW,
Cloud computing,
CAGR,
Industry,
COO,
Time,
Education,
Research,
Multimedia,
Investment,
Patient,
Adoption,
COVID-19,
Single-frequency network,
CEO,
VP,
DCT,
Digital technology,
Pharmaceutical industry,
Medical imaging,
DCTS PHILADELPHIA and NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Curavit Clinical Research, a virtual contract research organization (VCRO) that specializes in decentralized clinical trials (DCTs), today announced it raised $5 million in Series A funding to accelerate its growing portfolio of research in the global digital therapeutics (DTx) market (projected to grow at a CAGR of 31.4% through 2026). The new funding will be used to expand the company's DCT capabilities, partnerships, and market adoption of Curavit's virtual CRO services and platform for prescription and non-prescription digital therapeutics trials.
Key Points:
- The funding was led by early-stage technology investor Osage Venture Partners with additional investment from Royal Street Ventures and Narrow Gauge Ventures .
- "This is an important milestone for Curavit and the industry's continued momentum in digital therapeutics and decentralized approaches to clinical research," said Joel Morse, co-founder and CEO of Curavit.
- More than half of its customer base are emerging digital therapeutics companies whose clinical research needs align with Curavit's focus on virtual site services and DCT expertise.
- Curavit Clinical Research is a full-service, virtual contract research organization (VCRO), focused on designing and executing digital-first decentralized clinical trials (DCTs).
Tobacco,
TAS,
Heart Health Park,
DCT,
Cloud computing,
Degenerative disease,
Single-frequency network,
Technology,
Lark Health,
CEO,
Multimedia,
Diet,
COVID-19,
Cros,
Risk,
Thought,
Partnership,
Exercise,
Cardiovascular disease,
Patient,
CVD,
DCTS,
Health insurance,
Pharmaceutical industry,
Medical device,
Medical imaging,
Reddit,
Facebook,
Google,
Industry,
Instagram,
Pharma,
Lark BOSTON, Oct. 4, 2022 /PRNewswire/ -- Curavit Clinical Research, a virtual contract research organization (VCRO), announced that it is partnering with 1nHealth, a patient recruitment provider, to speed patient recruitment digitally for decentralized clinical trials (DCTs). 1nHealth integrates with Curavit's DCT platform, speeding trial enrollment and improving retention. Curavit and 1nHealth's first collaboration is for Lark Health's trial of an investigational digital therapeutic (DTx) for chronic cardiovascular disease.
Key Points:
- 1nHealth and Curavit surpass expectations by nearly 3x, enrolling 50 patients in Lark DTx trial in 10 days
BOSTON, Oct. 4, 2022 /PRNewswire/ -- Curavit Clinical Research , a virtual contract research organization (VCRO), announced that it is partnering with 1nHealth , a patient recruitment provider, to speed patient recruitment digitally for decentralized clinical trials (DCTs).
- "We are excited to partner with Curavit to improve patient recruitment by simplifying participant identification and enrollment through digital channels," said Dan Brenner , founder and CEO of 1nHealth.
- Together, Curavit and 1nHealth are working to overcome recruitment challenges and help usher in the next generation of decentralized clinical trials.
- Curavit Clinical Research is a full-service, virtual contract research organization (VCRO), focused on designing and executing digital-first decentralized clinical trials (DCTs).
Memory,
Patient,
Fibromyalgia,
CEO,
DCTS,
Single-frequency network,
DCT,
Population,
Lists of diseases,
Clinical trial,
Technology,
Fatigue,
Doctor of Philosophy,
Sleep,
Conditional sentence,
Cloud computing,
Multimedia,
Therapy,
Pharmaceutical industry,
Medical imaging BOSTON, June 28, 2022 /PRNewswire/ -- Curavit Clinical Research , a virtual contract research organization (VCRO), has been selected by digital therapeutics company, Swing Therapeutics , to be a virtual site for its pivotal trial of an investigational digital therapeutic (DTx) for fibromyalgia.
Key Points:
- BOSTON, June 28, 2022 /PRNewswire/ -- Curavit Clinical Research , a virtual contract research organization (VCRO), has been selected by digital therapeutics company, Swing Therapeutics , to be a virtual site for its pivotal trial of an investigational digital therapeutic (DTx) for fibromyalgia.
- Curavit will remotely recruit, screen, consent, and enroll participants in Swing's PROSPER-FM randomized clinical trial from across the United States.
- By eliminating physical and geographic barriers to trial participation and execution, Curavit can scale quickly and improve patient enrollment by at least 10x over a traditional trial, speeding trial execution.
- Swing developed its digital therapeutic with the goal of providing an accessible behavioral therapy option that can be used alongside medication, physical therapy, and other standard-of-care treatments.
Retrieved on:
Wednesday, September 29, 2021
Adoption,
News,
Therapy,
Clinical trial,
Decentralized Trials & Research Alliance,
Efficiency,
Brown University,
DCTS,
Boston Medical Center,
Health,
Culture,
Multimedia,
DCT,
MD,
DTRA,
CEO,
Leadership,
Technology,
View,
Research,
Machine learning,
Cloud computing,
Industry,
Education,
Travel,
Pharmaceutical industry BOSTON, Sept. 29, 2021 /PRNewswire/ -- Curavit Clinical Research , a virtual contract research organization (VCRO) that designs and executes decentralized clinical trials (DCTs), announced today that it has joined the Decentralized Trials & Research Alliance (DTRA) to further the advancement and adoption of decentralized clinicals.
Key Points:
- BOSTON, Sept. 29, 2021 /PRNewswire/ -- Curavit Clinical Research , a virtual contract research organization (VCRO) that designs and executes decentralized clinical trials (DCTs), announced today that it has joined the Decentralized Trials & Research Alliance (DTRA) to further the advancement and adoption of decentralized clinicals.
- Established in 2020, the DTRA enables collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research.
- It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods.
- Curavit Clinical Research is a virtual contract research organization (VCRO) that designs and executes Decentralized Clinical Trials (DCTs).
Retrieved on:
Wednesday, September 29, 2021
Adoption,
News,
Therapy,
Clinical trial,
Brown University,
Archive,
DCTS,
Boston Medical Center,
Health,
Massachusetts,
Hospital,
Multimedia,
Patient,
DTRA,
CEO,
Solution,
Global health,
Technology,
Johnson & Johnson,
View,
Research,
Machine learning,
Ecosystem,
Cloud computing,
Nextel Communications,
COO,
C3I,
Massachusetts General Hospital,
Travel,
Pharmaceutical industry,
Medical imaging,
Management Jay Collier brings more than 20 years of operational experience serving global clients in life sciences and clinical research.
Key Points:
- Jay Collier brings more than 20 years of operational experience serving global clients in life sciences and clinical research.
- Candice Del Rio , Curavit's new director of clinical operations, has more than 12 years of clinical research experience in academic , clinical, and industry settings.
- "It's an exciting time at Curavit as we grow along with the rapid evolution and adoption of decentralized clinical research," said Joel Morse, co-founder and CEO of Curavit.
- Curavit Clinical Research is a virtual contract research organization (VCRO) that designs and executes Decentralized Clinical Trials (DCTs).
Retrieved on:
Wednesday, September 9, 2020
BOSTON, Sept. 9, 2020 /PRNewswire/ -- Curavit Clinical Research, a virtual research organization, and eMoyo USA, LLC, the USA representative of eMoyo, a global leader in healthcare technology, today announced a partnership to pave the way for hearing research studies to continue during the COVID-19 pandemic.
Key Points:
- BOSTON, Sept. 9, 2020 /PRNewswire/ -- Curavit Clinical Research, a virtual research organization, and eMoyo USA, LLC, the USA representative of eMoyo, a global leader in healthcare technology, today announced a partnership to pave the way for hearing research studies to continue during the COVID-19 pandemic.
- Curavit's virtual team of audiologists remotely monitor the hearing of research subjects in their homes using the eMoyo KUDUwave Pro boothless audiometer.
- Working directly with the study subject, a Curavit audiologist initiates a telemedicine visit where they perform a thorough, high quality audiometric evaluation.
- The final data is securely transferred to the Curavit Study Team, where it is stored in a secure and validated system.
